We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




New Company to Promote Use of Cardiac PET

By HospiMedica staff writers
Posted on 16 Jun 2006
The Bracco Group (Milan, Italy), a developer of diagnostic imaging systems, and Integrated Medical Solutions, LLC (Sterling, VA, USA), a provider of positron emission tomography (PET) imaging centers in the United States, have formed a new company, Integrated Cardiac Solutions, LLC (ICS; Alexandria, VA, USA). More...
ICS will provide turnkey services that enable outpatient cardiology groups and heart centers to implement cardiac PET perfusion imaging technology for the detection of cardiovascular disease.

"The formation of ICS will lead an evolution in the field of cardiology,” said Carlo Medici, president and CEO of Bracco Diagnostics, Inc. (Princeton, NJ, USA). "Practices will now have an unprecedented opportunity to, first and foremost, offer expanded imaging services to their patients and, secondly, to improve the efficiency of their business. ICS and its wide array of services will be there to help them implement cardiac PET perfusion imaging every step of the way.”

Two recent clinical studies indicate that PET perfusion imaging is more accurate in the detection of coronary artery disease than the widely used single photon emission tomography (SPECT) perfusion imaging modality, particularly in women. Furthermore, the average time required for a cardiac PET perfusion test is about 30 minutes, versus three to four hours for the average cardiac SPECT perfusion scan, making cardiac PET more convenient for patients.

Cardiac PET perfusion imaging predominately uses the radionuclide rubidium-82, which can be derived from CardioGen-82 (rubidium Rb 82 generator), the only U.S Food and Drug Administration- (FDA)-approved generator-based cardiac PET perfusion agent. Over the past 18 months, the number of new CardioGen-82 sites has increased by nearly 90%. The adoption of cardiac PET in the outpatient setting is gaining favor among many cardiologists.

"I see ICS filling a missing piece in the rapidly emerging field of cardiac PET perfusion imaging. This venture will create a practical bridge, assisting practices in successfully implementing cardiac PET imaging as a significant and valued element in their patient management options,” stated Bill Abbott, vice president and general manager of nuclear medicine at Bracco Diagnostics.


Related Links:
Bracco Diagnostics
Integrated Cardiac Solutions

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mammography System (Analog)
MAM VENUS
Surgical Headlight
IsoTorch
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.